These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 16407111)

  • 1. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
    West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
    Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
    Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors.
    Möller E; Mandahl N; Mertens F; Panagopoulos I
    Genes Chromosomes Cancer; 2008 Jan; 47(1):21-5. PubMed ID: 17918257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.
    Fiocco U; Sfriso P; Lunardi F; Pagnin E; Oliviero F; Scagliori E; Cozzi L; Vezzù M; Molena B; Scanu A; Panziera C; Nardacchione R; Rubaltelli L; Dayer JM; Calabrese F; Punzi L
    Autoimmun Rev; 2010 Sep; 9(11):780-4. PubMed ID: 20620241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors.
    Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG
    Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
    Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
    Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
    Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
    Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.
    Ota T; Urakawa H; Kozawa E; Ikuta K; Hamada S; Tsukushi S; Shimoyama Y; Ishiguro N; Nishida Y
    Tumour Biol; 2015 Jul; 36(7):5361-7. PubMed ID: 25854167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors.
    Nilsson M; Höglund M; Panagopoulos I; Sciot R; Dal Cin P; Debiec-Rychter M; Mertens F; Mandahl N
    Virchows Arch; 2002 Nov; 441(5):475-80. PubMed ID: 12447678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel
    Mejbel H; Siegal GP; Wei S
    Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor.
    Dehner CA; Lo YC; Chopra S; Demicco EG; He K; Hirbe AC; Folpe AL; Chrisinger JSA
    Hum Pathol; 2024 Jan; 143():1-4. PubMed ID: 37993023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors.
    Panagopoulos I; Brandal P; Gorunova L; Bjerkehagen B; Heim S
    Int J Oncol; 2014 May; 44(5):1425-32. PubMed ID: 24604026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
    Thangaiah JJ; Koepplin JW; Folpe AL
    Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation.
    Huang HY; West RB; Tzeng CC; van de Rijn M; Wang JW; Chou SC; Huang WW; Eng HL; Lin CN; Yu SC; Wu JM; Lu CC; Li CF
    Clin Cancer Res; 2008 Oct; 14(19):6023-32. PubMed ID: 18829481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene.
    Brahmi M; Alberti L; Tirode F; Karanian M; Eberst L; Pissaloux D; Cassier P; Blay JY
    Ann Oncol; 2018 Jun; 29(6):1488-1489. PubMed ID: 29668829
    [No Abstract]   [Full Text] [Related]  

  • 19. Tenosynovial giant cell tumor.
    Kager M; Kager R; Fałek P; Fałek A; Szczypiór G; Niemunis-Sawicka J; Rzepecka-Wejs L; Starosławska E; Burdan F
    Folia Med Cracov; 2022; 62(2):93-107. PubMed ID: 36256897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of Illness Associated with Tenosynovial Giant Cell Tumors.
    Burton TM; Ye X; Parker ED; Bancroft T; Healey J
    Clin Ther; 2018 Apr; 40(4):593-602.e1. PubMed ID: 29580718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.